SYDNEY: Cellmid Limited has appointed C14 Consulting and PharmaVentures Limited to actively search for partners or buyers for Lyramid, Cellmid’s wholly owned subsidiary engaged in the research and development of treatments for inflammatory diseases and cancer targeting midkine, an embryonic growth factor implicated in a number of disease indications. The two agreements are independent from…